...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Microbiology >Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients
【24h】

Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients

机译：人类免疫缺陷病毒细胞DNA测序和血浆RNA测序都可用于检测抗逆转录病毒药物初治患者血样中的耐药突变

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Genotypic antiretroviral testing is recommended for newly infected drug-naive subjects, and the material of choice is plasma RNA. Since drug resistance mutations (DRMs) may persist longer in cellular DNA than in plasma RNA, we investigated whether the use of peripheral blood mononuclear cell (PBMC) human immunodeficiency virus (HIV) DNA increases the sensitivity of genotypic testing in antiretroviral-drug-naive subjects. We compared the rate of primary drug resistance in plasma RNA and PBMC DNA in 288 HIV type 1-infected drug-naive persons tested at a single clinical virology center from June 2004 to October 2006. Resistance in the plasma compartment to at least one drug was detected for 64 out of 288 (22.2%) naive patients and in the PBMC compartment for 56 (19.4%) patients. Overall, DRMs were found in 80 out of 288 (27.8%) patients. PBMC DRMs were present in plasma RNA from 16 subjects with wild-type virus infections. Another nine patients had additional DRMs in PBMCs with respect to those detected in plasma RNA. On the other hand, extra plasma DRMs were detected in PBMCs for 24 and 8 subjects with wild-type and drug-resistant virus, respectively. Resistance to more than one class of antiretroviral drug was detected by plasma and PBMC analysis for 25.0% and 36.2% of the subjects, respectively. Our data support the potential utility of genotypic resistance testing of PBMC DNA in conjunction with the currently recommended plasma RNA analysis.
机译：建议对刚感染新药的受试者进行基因型抗逆转录病毒测试，并且选择的材料是血浆RNA。由于耐药性突变（DRM）在细胞DNA中的持续时间可能长于血浆RNA，因此我们调查了外周血单核细胞（PBMC）人类免疫缺陷病毒（HIV）DNA的使用是否会提高抗逆转录病毒药物纯性基因型检测的敏感性科目。我们比较了2004年6月至2006年10月在单个临床病毒学中心测试的288名1型艾滋病毒感染者中血浆RNA和PBMC DNA的原发耐药率。血浆室对至少一种药物的耐药率为288例（22.2％）的初次患者中有64例被检出，PBMC隔室中有56例（19.4％）的患者被检出。总体而言，在288名患者中，有80名（27.8％）发现了DRM。 PBMC DRM存在于来自16位野生型病毒感染受试者的血浆RNA中。与血浆RNA中检测到的相比，另外九名患者在PBMC中具有其他DRM。另一方面，分别针对24和8位野生型和耐药病毒受试者在PBMC中检测到额外的血浆DRM。通过血浆和PBMC分析，分别对25.0％和36.2％的受试者检测到对一种以上抗逆转录病毒药物的耐药性。我们的数据支持PBMC DNA的基因型耐药性检测与当前推荐的血浆RNA分析结合使用的潜在效用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号